Application Progress of Spatially Resolved Metabolomics in Disease Diagnosis Research

doi:10.13560/j.cnki.biotech.bull.1985.2023-0351

Abstract

Abstract:

Mass spectrometry imaging（MSI）based on spatially resolved metabolomics（SRM）has been recently developed to be a powerful technology. SRM can not only directly identify and quantify the metabolites in animal and plant tissues or cells in situ, but also use overall or local features of the image to determine the structure, content, spatiotemporal dynamic change, and spatial distribution of metabolites. It also may identify potential metabolic biomarkers. This technology has the advantages of high sensitivity, high resolution, judicious visualization and label-free, and therefore has been more and more widely applied in clinical disease diagnosis and research. This review summarizes some of the technological advances of SRM in recent years, and its emerging application in the fields of tumor, neuropsychiatric disorder, diabetes mellitus, among others, in an attempt to guide future application of SRM in disease diagnosis.

Key words: spatially resolved metabolomics（SRM）, mass spectrometry imaging（MSI）, disease diagnosis, metabolite, biomarker

HE Shi-yu, ZENG Zhong-da, LI Bo-yan. Application Progress of Spatially Resolved Metabolomics in Disease Diagnosis Research[J]. Biotechnology Bulletin, 2024, 40(1): 145-159.

Figures/Tables 6

References 103

[1]	Peng B, Li H, Peng XX. Functional metabolomics: from biomarker discovery to metabolome reprogramming[J]. Protein Cell, 2015, 6(9): 628-637. doi: 10.1007/s13238-015-0185-x pmid: 26135925
[2]	Sumner LW, Yang DS, Bench BJ, et al. Spatially resolved plant metabolomics[M]//Annual Plant Reviews Volume 43. Oxford, UK: Wiley-Blackwell, 2011: 343-366.
[3]	Gao SQ, Zhao JH, Guan Y, et al. Mass spectrometry imaging technology in metabolomics: a systematic review[J]. Biomed Chromatogr, 2023, 37(7): e5494. doi: 10.1002/bmc.v37.7 URL
[4]	Laíns I, Gantner M, Murinello S, et al. Metabolomics in the study of retinal health and disease[J]. Prog Retin Eye Res, 2019, 69: 57-79. doi: S1350-9462(18)30021-1 pmid: 30423446
[5]	Ma SY, Leng YX, Li XP, et al. High spatial resolution mass spectrometry imaging for spatial metabolomics: advances, challenges, and future perspectives[J]. Trend Anal Chem, 2023, 159: 116902. doi: 10.1016/j.trac.2022.116902 URL
[6]	Beccaria M, Cabooter D. Current developments in LC-MS for pharmaceutical analysis[J]. Analyst, 2020, 145(4): 1129-1157. doi: 10.1039/c9an02145k pmid: 31971527
[7]	Cui L, Lu HT, Lee YH. Challenges and emergent solutions for LC-MS/MS based untargeted metabolomics in diseases[J]. Mass Spectrom Rev, 2018, 37(6): 772-792. doi: 10.1002/mas.21562 pmid: 29486047
[8]	Watson BS, Urbanczyk-Wochniak E, Lei Z, et al. Spatially resolved metabolomics and proteomics of Medicago truncatula border cells and root tips[C]. Joint Annual Meeting of the American-Fern-Society/American-Society-of-Plant-Biologists/American-Society-of-Plant-Taxonomists/Botanical-Society-of-America, 2007: 78.
[9]	Lee YJ, Perdian DC, Song ZH, et al. Use of mass spectrometry for imaging metabolites in plants[J]. Plant J, 2012, 70(1): 81-95. doi: 10.1111/tpj.2012.70.issue-1 URL
[10]	Taylor MJ, Lukowski JK, Anderton CR. Spatially resolved mass spectrometry at the single cell: recent innovations in proteomics and metabolomics[J]. J Am Soc Mass Spectrom, 2021, 32(4): 872-894. doi: 10.1021/jasms.0c00439 URL
[11]	Sun CL, Li TG, Song XW, et al. Spatially resolved metabolomics to discover tumor-associated metabolic alterations[J]. Proc Natl Acad Sci USA, 2019, 116(1): 52-57. doi: 10.1073/pnas.1808950116 pmid: 30559182
[12]	Fox BW, Schroeder FC. Toward spatially resolved metabolomics[J]. Nat Chem Biol, 2020, 16(10): 1039-1040. doi: 10.1038/s41589-020-00650-0 pmid: 32943790
[13]	Zang QC, Sun CL, Chu XP, et al. Spatially resolved metabolomics combined with multicellular tumor spheroids to discover cancer tissue relevant metabolic signatures[J]. Anal Chim Acta, 2021, 1155: 338342. doi: 10.1016/j.aca.2021.338342 URL
[14]	Chen F, Dai XD, Zhou CC, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma[J]. Gut, 2022, 71(7): 1315-1325. doi: 10.1136/gutjnl-2020-323476 URL
[15]	Santoro AL, Drummond RD, Silva IT, et al. In situ DESI-MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions[J]. Cancer Res, 2020, 80(6): 1246-1257. doi: 10.1158/0008-5472.CAN-18-3574 URL
[16]	Andersen MK, Høiem TS, Claes BSR, et al. Spatial differentiation of metabolism in prostate cancer tissue by MALDI-TOF MSI[J]. Cancer Metab, 2021, 9(1): 9. doi: 10.1186/s40170-021-00242-z pmid: 33514438
[17]	Shen J, Sun N, Zens P, et al. Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients[J]. Cancer Commun, 2022, 42(6): 517-535. doi: 10.1002/cac2.v42.6 URL
[18]	Wang ZH, Fu WQ, Huo ML, et al. Spatial-resolved metabolomics reveals tissue-specific metabolic reprogramming in diabetic nephropathy by using mass spectrometry imaging[J]. Acta Pharm Sin B, 2021, 11(11): 3665-3677. doi: 10.1016/j.apsb.2021.05.013 pmid: 34900545
[19]	Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11): 1181-1189. doi: 10.1080/004982599238047 pmid: 10598751
[20]	Bujak R, Struck-Lewicka W, Markuszewski MJ, et al. Metabolomics for laboratory diagnostics[J]. J Pharm Biomed Anal, 2015, 113: 108-120. doi: 10.1016/j.jpba.2014.12.017 pmid: 25577715
[21]	Giera M, Dos Santos FB, Siuzdak G. Metabolite-induced protein expression guided by metabolomics and systems biology[J]. Cell Metab, 2018, 27(2): 270-272. doi: S1550-4131(18)30051-2 pmid: 29414681
[22]	Azad RK, Shulaev V. Metabolomics technology and bioinformatics for precision medicine[J]. Brief Bioinform, 2019, 20(6): 1957-1971. doi: 10.1093/bib/bbx170 pmid: 29304189
[23]	Brindle JT, Antti H, Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics[J]. Nat Med, 2002, 8(12): 1439-1444. doi: 10.1038/nm1202-802 pmid: 12447357
[24]	Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon carcinoma—deregulation of TCA cycle and amino acid turnover[J]. Mol Cancer, 2008, 7: 72. doi: 10.1186/1476-4598-7-72 URL
[25]	Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression[J]. Nature, 2009, 457(7231): 910-914. doi: 10.1038/nature07762
[26]	Porta Siegel T, Ellis SR. Mass spectrometry imaging 2.0[J]. Anal Bioanal Chem, 2021, 413(10): 2597-2598. doi: 10.1007/s00216-021-03293-9 pmid: 33758987
[27]	He MJ, Pu WJ, Wang X, et al. Comparing DESI-MSI and MALDI-MSI mediated spatial metabolomics and their applications in cancer studies[J]. Front Oncol, 2022, 12: 891018. doi: 10.3389/fonc.2022.891018 URL
[28]	郭帅. 质谱成像原位探究肿瘤相关代谢物谱[D]. 北京: 北京协和医学院, 2015.
	Guo S. In-situ exploration of tumor-related metabolites by mass spectrometry imaging[D]. Beijing: Peking Union Medical College, 2015.
[29]	金涛, 潘本松, 聂洪港. 基质辅助激光解吸电离-质谱成像技术(MALDI-MSI)及其在脑神经性疾病研究中的应用[J]. 计量科学与技术, 2022, 66(3): 3-22.
	Jin T, Pan BS, Nie HG. Matrix-assisted laser desorption/ionization mass spectrometry imaging and its application in the study of brain neurological disease[J]. Metrol Sci Technol, 2022, 66(3): 3-22.
[30]	Kompauer M, Heiles S, Spengler B. Atmospheric pressure MALDI mass spectrometry imaging of tissues and cells at 1.4-μm lateral resolution[J]. Nat Methods, 2017, 14(1): 90-96. doi: 10.1038/nmeth.4071 pmid: 27842060
[31]	He Q, Sun CR, Liu J, et al. MALDI-MSI analysis of cancer drugs: significance, advances, and applications[J]. Trend Anal Chem, 2021, 136: 116183. doi: 10.1016/j.trac.2021.116183 URL
[32]	Kulkarni P, Wilschut RA, Verhoeven KJF, et al. LAESI mass spectrometry imaging as a tool to differentiate the root metabolome of native and range-expanding plant species[J]. Planta, 2018, 248(6): 1515-1523. doi: 10.1007/s00425-018-2989-4 pmid: 30140978
[33]	Sämfors S, Fletcher JS. Lipid diversity in cells and tissue using imaging SIMS[J]. Annu Rev Anal Chem, 2020, 13(1): 249-271. doi: 10.1146/anchem.2020.13.issue-1 URL
[34]	Vickerman JC. Molecular imaging and depth profiling by mass spectrometry—SIMS, MALDI or DESI?[J]. Analyst, 2011, 136(11): 2199-2217. doi: 10.1039/c1an00008j pmid: 21461433
[35]	He JM, Tang F, Luo ZG, et al. Air flow assisted ionization for remote sampling of ambient mass spectrometry and its application[J]. Rapid Commun Mass Spectrom, 2011, 25(7): 843-850. doi: 10.1002/rcm.v25.7 URL
[36]	He JM, Sun CL, Li TG, et al. A sensitive and wide coverage ambient mass spectrometry imaging method for functional metabolites based molecular histology[J]. Adv Sci, 2018, 5(11): 1800250. doi: 10.1002/advs.v5.11 URL
[37]	Vandereyken K, Sifrim A, Thienpont B, et al. Methods and applications for single-cell and spatial multi-omics[J]. Nat Rev Genet, 2023, 24(8): 494-515. doi: 10.1038/s41576-023-00580-2 pmid: 36864178
[38]	Alexandrov T. Spatial metabolomics and imaging mass spectrometry in the age of artificial intelligence[J]. Annu Rev Biomed Data Sci, 2020, 3: 61-87. doi: 10.1146/annurev-biodatasci-011420-031537 pmid: 34056560
[39]	Shariatgorji R, Nilsson A, Fridjonsdottir E, et al. Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging[J]. Nat Protoc, 2021, 16(7): 3298-3321. doi: 10.1038/s41596-021-00538-w pmid: 34075230
[40]	Huang LJ, Mao XX, Sun CL, et al. A graphical data processing pipeline for mass spectrometry imaging-based spatially resolved metabolomics on tumor heterogeneity[J]. Anal Chim Acta, 2019, 1077: 183-190. doi: S0003-2670(19)30683-X pmid: 31307708
[41]	Sun CL, Wang FK, Zhang Y, et al. Mass spectrometry imaging-based metabolomics to visualize the spatially resolved reprogramming of carnitine metabolism in breast cancer[J]. Theranostics, 2020, 10(16): 7070-7082. doi: 10.7150/thno.45543 pmid: 32641979
[42]	Butler LM, Perone Y, Dehairs J, et al. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention[J]. Adv Drug Deliv Rev, 2020, 159: 245-293. doi: 10.1016/j.addr.2020.07.013 URL
[43]	Ma X, Fernández FM. Advances in mass spectrometry imaging for spatial cancer metabolomics[J]. Mass Spectrom Rev, 2022: e21804.
[44]	Eberlin LS, Margulis K, Planell-Mendez I, et al. Pancreatic cancer surgical resection margins: molecular assessment by mass spectrometry imaging[J]. PLoS Med, 2016, 13(8): e1002108. doi: 10.1371/journal.pmed.1002108 URL
[45]	Qi KK, Lv YM, Ren Y, et al. Cholesterol was identified as a biomarker in human melanocytic nevi using DESI and DESI/PI mass spectrometry imaging[J]. Talanta, 2021, 231: 122380. doi: 10.1016/j.talanta.2021.122380 URL
[46]	Drake RR, McDowell C, West C, et al. Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry[J]. J Mass Spectrom, 2020, 55(4): e4490. doi: 10.1002/jms.v55.4 URL
[47]	Bourgognon JM, Steinert JR. The metabolome identity: basis for discovery of biomarkers in neurodegeneration[J]. Neural Regen Res, 2019, 14(3): 387-390. doi: 10.4103/1673-5374.245464 URL
[48]	Yon M, Decoville M, Sarou-Kanian V, et al. Spatially-resolved metabolic profiling of living Drosophila in neurodegenerative conditions using ¹H magic angle spinning NMR[J]. Sci Rep, 2020, 10(1): 9516. doi: 10.1038/s41598-020-66218-z
[49]	Pang XC, Gao SS, Ga M, et al. Mapping metabolic networks in the brain by ambient mass spectrometry imaging and metabolomics[J]. Anal Chem, 2021, 93(17): 6746-6754. doi: 10.1021/acs.analchem.1c00467 URL
[50]	Wang XQ, Yang XL, Hou ZH, et al. Whole-brain mapping of metabolic alterations in a mouse model of Alzheimer's disease by desorption electrospray ionization mass spectrometry imaging[J]. Talanta, 2023, 253: 124046. doi: 10.1016/j.talanta.2022.124046 URL
[51]	Seneviratne HK, Wheeler A, Eberhard C, et al. Revealing sex and Alzheimer's disease-related changes in the spatial localization of brain lipids in mice using mass spectrometry imaging[J]. FASEBJ, 2022, 36(S1). DOI: 10.1096/fasebj.2022.36.S1.R4131.
[52]	Ajith A, Mondal S, Chattopadhyay S, et al. Mass spectrometry imaging deciphers dysregulated lipid metabolism in the human hippocampus affected by temporal lobe epilepsy[J]. ACS Chem Neurosci, 2021, 12(21): 4187-4194. doi: 10.1021/acschemneuro.1c00587 URL
[53]	Bergholt MS, Serio A, McKenzie JS, et al. Correlated heterospectral lipidomics for biomolecular profiling of remyelination in multiple sclerosis[J]. ACS Cent Sci, 2018, 4(1): 39-51. doi: 10.1021/acscentsci.7b00367 URL
[54]	Vendramini PH, Gattaz WF, Schmitt A, et al. Pioneering ambient mass spectrometry imaging in psychiatry: potential for new insights into schizophrenia[J]. Schizophr Res, 2016, 177(1/2/3): 67-69. doi: 10.1016/j.schres.2015.10.019 URL
[55]	Mouchlianitis E, McCutcheon R, Howes OD. Brain-imaging studies of treatment-resistant schizophrenia: a systematic review[J]. Lancet Psychiatry, 2016, 3(5): 451-463. doi: 10.1016/S2215-0366(15)00540-4 pmid: 26948188
[56]	Zheng HL, Sang YQ, Houk KN, et al. Mechanism and origins of enantioselectivities in spirobiindane-based hypervalent iodine(III)-induced asymmetric dearomatizing spirolactonizations[J]. J Am Chem Soc, 2019, 141(40): 16046-16056. doi: 10.1021/jacs.9b08243 pmid: 31514501
[57]	Bergman HM, Lindfors L, Palm F, et al. Metabolite aberrations in early diabetes detected in rat kidney using mass spectrometry imaging[J]. Anal Bioanal Chem, 2019, 411(13): 2809-2816. doi: 10.1007/s00216-019-01721-5
[58]	Miyamoto S, Hsu CC, Hamm G, et al. Mass spectrometry imaging reveals elevated glomerular ATP/AMP in diabetes/obesity and identifies sphingomyelin as a possible mediator[J]. eBioMedicine, 2016, 7: 121-134. doi: 10.1016/j.ebiom.2016.03.033 pmid: 27322466
[59]	Zhang X, Liu YH, Yang S, et al. Comparison of local metabolic changes in diabetic rodent kidneys using mass spectrometry imaging[J]. Metabolites, 2023, 13(3): 324. doi: 10.3390/metabo13030324 URL
[60]	Huo ML, Wang ZH, Fu WQ, et al. Spatially resolved metabolomics based on air-flow-assisted desorption electrospray ionization-mass spectrometry imaging reveals region-specific metabolic alterations in diabetic encephalopathy[J]. J Proteome Res, 2021, 20(7): 3567-3579. doi: 10.1021/acs.jproteome.1c00179 URL
[61]	Meng XY, Liu YH, Huo ML, et al. Mapping of fatty aldehydes in the diabetic rat brain using on-tissue chemical derivatization and air-flow-assisted desorption electrospray ionization-mass spectrometry imaging[J]. J Proteome Res, 2023, 22(1): 36-46. doi: 10.1021/acs.jproteome.2c00445 pmid: 36564034
[62]	Tans R, Dey S, Dey NS, et al. Spatially resolved immunometabolism to understand infectious disease progression[J]. Front Microbiol, 2021, 12: 709728. doi: 10.3389/fmicb.2021.709728 URL
[63]	Fincher JA, Jones DR, Korte AR, et al. Mass spectrometry imaging of lipids in human skin disease model hidradenitis suppurativa by laser desorption ionization from silicon nanopost arrays[J]. Sci Rep, 2019, 9(1): 17508. doi: 10.1038/s41598-019-53938-0 pmid: 31767918
[64]	Park ES, Lee JH, Hong JH, et al. Phosphatidylcholine alteration identified using MALDI imaging MS in HBV-infected mouse livers and virus-mediated regeneration defects[J]. PLoS One, 2014, 9(8): e103955. doi: 10.1371/journal.pone.0103955 URL
[65]	Ciurli A, Liebl M, Derks RJE, et al. Spatially resolved sampling for untargeted metabolomics: a new tool for salivomics[J]. iScience, 2021, 24(7): 102768. doi: 10.1016/j.isci.2021.102768 URL
[66]	Mutuku SM, Spotbeen X, Trim PJ, et al. Unravelling prostate cancer heterogeneity using spatial approaches to lipidomics and transcriptomics[J]. Cancers, 2022, 14(7): 1702. doi: 10.3390/cancers14071702 URL
[67]	Young RSE, Claes BSR, Bowman AP, et al. Isomer-resolved imaging of prostate cancer tissues reveals specific lipid unsaturation profiles associated with lymphocytes and abnormal prostate epithelia[J]. Front Endocrinol, 2021, 12: 689600. doi: 10.3389/fendo.2021.689600 URL
[68]	Zhang MT, Zhang YL, Wang HJ, et al. Mass spectrometry imaging technology and its application in breast cancer research[J]. Se Pu, 2021, 39(6): 578-587.
[69]	Gonçalves JPL, Bollwein C, Noske A, et al. Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging[J]. Int J Mol Sci, 2023, 24(3): 2860. doi: 10.3390/ijms24032860 URL
[70]	Tu AQ, Said N, Muddiman DC. Spatially resolved metabolomic characterization of muscle invasive bladder cancer by mass spectrometry imaging[J]. Metabolomics, 2021, 17(8): 70. doi: 10.1007/s11306-021-01819-x pmid: 34287708
[71]	Kaufmann M, Iaboni N, Jamzad A, et al. Metabolically active zones involving fatty acid elongation delineated by DESI-MSI correlate with pathological and prognostic features of colorectal cancer[J]. Metabolites, 2023, 13(4): 508. doi: 10.3390/metabo13040508 URL
[72]	Zou L, Wang LL, Guo L, et al. Small molecules as potential biomarkers of early gastric cancer: a mass spectrometry imaging approach[J]. Clin Chim Acta, 2022, 534: 35-42. doi: 10.1016/j.cca.2022.06.032 pmid: 35810803
[73]	Sun CL, Wang AQ, Zhou YH, et al. Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer[J]. Nat Commun, 2023, 14(1): 2692. doi: 10.1038/s41467-023-38360-5 pmid: 37164975
[74]	He MJ, Pu WJ, Wang X, et al. Spatial metabolomics on liver cirrhosis to hepatocellular carcinoma progression[J]. Cancer Cell Int, 2022, 22(1): 366. doi: 10.1186/s12935-022-02775-9 pmid: 36419080
[75]	Martini T, Naef F, Tchorz JS. Spatiotemporal metabolic liver zonation and consequences on pathophysiology[J]. Annu Rev Pathol, 2023, 18: 439-466. doi: 10.1146/annurev-pathmechdis-031521-024831 pmid: 36693201
[76]	Neumann JM, Freitag H, Hartmann JS, et al. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics[J]. J Cancer Res Clin Oncol, 2022, 148(2): 351-360. doi: 10.1007/s00432-021-03834-w
[77]	Wang HJ, Li B, Zhang MT, et al. Mass spectrometry and mass spectrometry imaging-based thyroid cancer analysis[J]. J Anal Test, 2022, 6(3): 235-246. doi: 10.1007/s41664-022-00218-y
[78]	Yang XH, Song XW, Zhang XX, et al. In situ DESI-MSI lipidomic profiles of mucosal margin of oral squamous cell carcinoma[J]. eBioMedicine, 2021, 70: 103529. doi: 10.1016/j.ebiom.2021.103529 URL
[79]	Ikegawa M, Kakuda N, Miyasaka T, et al. Mass spectrometry imaging in Alzheimer's disease[J]. Brain Connect, 2023. DOI: 10.1089/brain.2022.0057.
[80]	Andrews WT, Donahue D, Holmes A, et al. In situ metabolite and lipid analysis of GluN2D^-/- and wild-type mice after ischemic stroke using MALDI MSI[J]. Anal Bioanal Chem, 2020, 412(24): 6275-6285. doi: 10.1007/s00216-020-02477-z
[81]	Mallah K, Zibara K, Kerbaj C, et al. Neurotrauma investigation through spatial omics guided by mass spectrometry imaging: target identification and clinical applications[J]. Mass Spectrom Rev, 2023, 42(1): 189-205. doi: 10.1002/mas.v42.1 URL
[82]	Harkin C, Smith KW, MacKay CL, et al. Spatial localization of β-unsaturated aldehyde markers in murine diabetic kidney tissue by mass spectrometry imaging[J]. Anal Bioanal Chem, 2022, 414(22): 6657-6670. doi: 10.1007/s00216-022-04229-7 pmid: 35881173
[83]	Li W, Luo JC, Peng FD, et al. Spatial metabolomics identifies lipid profiles of human carotid atherosclerosis[J]. Atherosclerosis, 2023, 364: 20-28. doi: 10.1016/j.atherosclerosis.2022.11.019 URL
[84]	Bonelli R, Woods SM, Lockwood S, et al. Spatial distribution of metabolites in the retina and its relevance to studies of metabolic retinal disorders[J]. Metabolomics, 2023, 19(2): 10. doi: 10.1007/s11306-022-01969-6 pmid: 36745234
[85]	Ren J, Li HW, Chen L, et al. Mass spectrometry imaging-based single-cell lipidomics profiles metabolic signatures of heart failure[J]. Research, 2023, 6: 0019. doi: 10.34133/research.0019 pmid: 37040505
[86]	Goodwin RJA. Sample preparation for mass spectrometry imaging: small mistakes can lead to big consequences[J]. J Proteomics, 2012, 75(16): 4893-4911. doi: S1874-3919(12)00218-7 pmid: 22554910
[87]	González-Riano C, Dudzik D, Garcia A, et al. Recent developments along the analytical process for metabolomics workflows[J]. Anal Chem, 2020, 92(1): 203-226. doi: 10.1021/acs.analchem.9b04553 pmid: 31625723
[88]	Amstalden van Hove ER, Smith DF, Heeren RMA. A concise review of mass spectrometry imaging[J]. J Chromatogr A, 2010, 1217(25): 3946-3954. doi: 10.1016/j.chroma.2010.01.033 pmid: 20223463
[89]	Buchberger AR, DeLaney K, Johnson J, et al. Mass spectrometry imaging: a review of emerging advancements and future insights[J]. Anal Chem, 2018, 90(1): 240-265. doi: 10.1021/acs.analchem.7b04733 pmid: 29155564
[90]	Zheng FJ, Zhao XJ, Zeng ZD, et al. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography-mass spectrometry[J]. Nat Protoc, 2020, 15(8): 2519-2537. doi: 10.1038/s41596-020-0341-5 pmid: 32581297
[91]	Grillo F, Pigozzi S, Ceriolo P, et al. Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections[J]. Histochem Cell Biol, 2015, 144(1): 93-99. doi: 10.1007/s00418-015-1316-4 pmid: 25757745
[92]	Bookmeyer C, Röhling U, Dreisewerd K, et al. Single-photon-induced post-ionization to boost ion yields in MALDI mass spectrometry imaging[J]. Angew Chem Int Ed Engl, 2022, 61(34): e202202165. doi: 10.1002/anie.v61.34 URL
[93]	Michael JA, Mutuku SM, Ucur B, et al. Mass spectrometry imaging of lipids using MALDI coupled with plasma-based post-ionization on a trapped ion mobility mass spectrometer[J]. Anal Chem, 2022, 94(50): 17494-17503. doi: 10.1021/acs.analchem.2c03745 pmid: 36473074
[94]	Mou HZ, Pan JB, Zhao CL, et al. Nanometer resolution mass spectro-microtomography for In-depth anatomical profiling of single cells[J]. ACS Nano, 2023, 17(11): 10535-10545. doi: 10.1021/acsnano.3c01449 URL
[95]	Suvannapruk W, Edney MK, Kim DH, et al. Single-cell metabolic profiling of macrophages using 3D OrbiSIMS: correlations with phenotype[J]. Anal Chem, 2022, 94(26): 9389-9398. doi: 10.1021/acs.analchem.2c01375 pmid: 35713879
[96]	Lewis HM, Gupta P, Saunders KDG, et al. Nanocapillary sampling coupled to liquid chromatography mass spectrometry delivers single cell drug measurement and lipid fingerprints[J]. Analyst, 2023, 148(5): 1041-1049. doi: 10.1039/D2AN01732F URL
[97]	Unsihuay D, Mesa Sanchez D, Laskin J. Quantitative mass spectrometry imaging of biological systems[J]. Annu Rev Phys Chem, 2021, 72: 307-329. doi: 10.1146/annurev-physchem-061020-053416 pmid: 33441032
[98]	Ju R, Liu XY, Zheng FJ, et al. A graph density-based strategy for features fusion from different peak extract software to achieve more metabolites in metabolic profiling from high-resolution mass spectrometry[J]. Anal Chim Acta, 2020, 1139: 8-14. doi: 10.1016/j.aca.2020.09.029 pmid: 33190713
[99]	Zhang J, Ma L, Li BY, et al. Identification of biomarkers for risk assessment of arsenicosis based on untargeted metabolomics and machine learning algorithms[J]. Sci Total Environ, 2023, 870: 161861. doi: 10.1016/j.scitotenv.2023.161861 URL
[100]	Wu WY, Hou JJ, Zhang ZJ, et al. Information entropy-based strategy for the quantitative evaluation of extensive hyperspectral images to better unveil spatial heterogeneity in mass spectrometry imaging[J]. Anal Chem, 2022, 94(29): 10355-10366. doi: 10.1021/acs.analchem.2c00370 pmid: 35830352
[101]	Zhao XJ, Zeng ZD, Chen AM, et al. Comprehensive strategy to construct In-house database for accurate and batch identification of small molecular metabolites[J]. Anal Chem, 2018, 90(12): 7635-7643. doi: 10.1021/acs.analchem.8b01482 pmid: 29807420
[102]	Rappez L, Stadler M, Triana S, et al. SpaceM reveals metabolic states of single cells[J]. Nat Methods, 2021, 18(7): 799-805. doi: 10.1038/s41592-021-01198-0 pmid: 34226721
[103]	Yuan ZY, Zhou QM, Cai LS, et al. SEAM is a spatial single nuclear metabolomics method for dissecting tissue microenvironment[J]. Nat Methods, 2021, 18(10): 1223-1232. doi: 10.1038/s41592-021-01276-3 pmid: 34608315

检测方法 Detection method	NMR	GC-MS	LC-MS	MSI
灵敏度	一般	较高	高	高
分辨率	较高	较高	高	高，可达μm级
重现性	好	较好	较好	好
样品前处理方式	较简单，无需衍生化	繁琐，样品需做衍生化处理	简单	简单，样品无需衍生化且无需标记
适用范围	分子物质，可检测糖类、氨基酸类等含氢水溶性小分子	分子物质，可检测极性小的易挥发、可衍生化且不易降解的含活性氢基团物质	分子物质，可检测极性大的化合物，或不稳定、难挥发、难衍生化的物质	组织、单细胞均可

检测方法 Detection method	NMR	GC-MS	LC-MS	MSI
灵敏度	一般	较高	高	高
分辨率	较高	较高	高	高，可达μm级
重现性	好	较好	较好	好
样品前处理方式	较简单，无需衍生化	繁琐，样品需做衍生化处理	简单	简单，样品无需衍生化且无需标记
适用范围	分子物质，可检测糖类、氨基酸类等含氢水溶性小分子	分子物质，可检测极性小的易挥发、可衍生化且不易降解的含活性氢基团物质	分子物质，可检测极性大的化合物，或不稳定、难挥发、难衍生化的物质	组织、单细胞均可

类别 Item	MALDI-MSI	SIMS imaging	LAESI-MSI	DESI-MSI
离子源	MALDI	SIMS	LAESI	DESI
电离类型	软	静态：软动态：硬	软	软
空间分辨率	最低可至1.4，多数 5-100	静态：0.1-10 动态：0.01-1	2.4-200	最低可至10-20，多数50-200
样品制备	需要	需要	无需	几乎无需
质量范围/Da	300-100 000	静态：1-3 000 动态：1-250	1-5 000	100-10 000
扫描深度/μm	0.1-20	0.5-10	0.1-50	1-500
检测限	amol-fmol	fmol-pmol	fmol-pmol	fmol-pmol
适用范围	代谢物、脂类、多聚糖、多肽、蛋白质、核酸	元素、代谢物、脂类	代谢物、脂类、多肽、含水量大的样本	代谢物、脂类、多肽
定量能力	可行	静态：困难动态：可行	可行	可行
工作环境	常压/真空	真空	常压	常压

类别 Item	MALDI-MSI	SIMS imaging	LAESI-MSI	DESI-MSI
离子源	MALDI	SIMS	LAESI	DESI
电离类型	软	静态：软动态：硬	软	软
空间分辨率	最低可至1.4，多数 5-100	静态：0.1-10 动态：0.01-1	2.4-200	最低可至10-20，多数50-200
样品制备	需要	需要	无需	几乎无需
质量范围/Da	300-100 000	静态：1-3 000 动态：1-250	1-5 000	100-10 000
扫描深度/μm	0.1-20	0.5-10	0.1-50	1-500
检测限	amol-fmol	fmol-pmol	fmol-pmol	fmol-pmol
适用范围	代谢物、脂类、多聚糖、多肽、蛋白质、核酸	元素、代谢物、脂类	代谢物、脂类、多肽、含水量大的样本	代谢物、脂类、多肽
定量能力	可行	静态：困难动态：可行	可行	可行
工作环境	常压/真空	真空	常压	常压

疾病类型 Disease type	研究对象 Research object	研究技术与方法 Research techniques and methods	关键代谢物 Key metabolite	参与途径 Ways of participation	文献 Reference
肿瘤	前列腺癌	MALDI-MSI、DESI-MSI	丝裂原活化蛋白激酶/细胞外信号调节激酶、硫酸胆固醇、磷脂酰肌醇和胆绿素还原酶B，多种磷脂类丰度增加，柠檬酸盐水平显著下降	Mitogen-activated protein kinase（MAPK）, Phosphatidylinositol 3-kinase（PI3K）代谢通路	[16,66 -67]
	乳腺癌	MALDI-MSI、DESI-MSI	L-肉碱和短链酰基肉碱，肉碱棕榈酰转移酶1A、肉碱/酰基肉碱转移酶和肉碱棕榈酰转移酶2，脂肪酸和磷脂组成明显变化	脂肪酸β-氧化途径	[42,68 -69]
	膀胱癌	红外基质辅助激光解吸电喷雾电离质谱成像IR-MALDESI MSI	游离脂肪酸显著增加，肌醇磷脂、磷脂酸聚集	脂质代谢	[70]
	结直肠癌	AFADESI-MSI、MALDI-MSI、DESI-MSI	N,O-双-（三甲基甲硅烷基）苯丙氨酸丰度上调，长链脂肪酸、极长链脂肪酸和多种氧化磷脂增加	脂质代谢	[14,71]
	胃癌	液体提取-电声喷雾电离-傅里叶变换离子回旋共振质谱成像LE-ESSI MSI FTICR-MSI、MALDI-MSI、DESI-MSI	血清磷脂酰胆碱（32:0）、磷脂酰胆碱（34:3）	胆碱代谢	[72-73]
	肝细胞癌	AFADESI-MSI	有机酸及其衍生物丰度上调，不同微区存在差异代谢物	氨基酸代谢（β-丙氨酸代谢、精氨酸和脯氨酸代谢），胆碱代谢，甘油磷脂代谢	[74-75]
	非小细胞肺癌	2D-imaging MSI	鞘磷脂和多种磷脂酰丝氨酸减少，以及磷脂酰乙醇胺和磷脂酰胆碱种类增加	磷脂谱代谢差异	[76]
	甲状腺癌	2D DESI-MSI	神经酰胺和甘油磷酸肌醇相对丰度上调	脂质代谢	[77]
	口腔鳞状细胞癌	DESI-MSI	14种特征脂质代谢物	脂质代谢	[78]
神经精神疾病	阿尔茨海默病	TOF-SIMS imaging、MALDI-MSI	硫苷脂丰度下调，腺嘌呤和腺嘌呤核糖核酸浓度显著下降，溶血磷脂酰肌醇以及花生四烯酸缀合的磷脂酰肌醇显示出在Aβ斑块特异性定位	嘌呤代谢途径，脂质与β淀粉样蛋白（Aβ）肽异常沉积驱动阿尔茨海默病发生发展的机制	[79]
	癫痫	DESI-MSI	磷脂酰胆碱和磷脂酰乙醇胺表达减少	Kennedy代谢途径	[53]
	中风	MALDI-MSI	谷氨酸、N-乙酰天冬氨酸呈差异性变化	氨基酸代谢	[80]
	精神分裂症	DESI-MSI	磷脂酰胆碱水平降低	胆碱代谢	[55]
	创伤性脑损伤	MALDI-MSI	酰基肉碱代谢差异	脂肪酸代谢	[81]
糖尿病及其并发症	糖尿病	MALDI-MSI、 Nano-DESI-MSI	肾小球三磷酸腺苷与单磷酸腺苷（ATP/AMP）的比例增加，且鞘磷脂（d18:1/16:0）在糖尿病大鼠中累积、酰基肉碱在肾组织中明显增加	鞘脂代谢	[59]
	糖尿病肾病	液体萃取表面分析质谱成像LESA-MSI、AFADESI-MSI、MALDI-MSI	多种脂肪酸、磷脂类代谢物有明显差异性改变且改变具有区域特异性，肉碱类和胆碱类代谢物也发生表达差异	亚油酸代谢、花生四烯酸代谢、α-亚麻酸代谢、甘油磷脂代谢和三羧酸循环（TCA）	[18,60,82]
	糖尿病脑病	AFADESI-MSI	脂肪醛（Fals）在DE大鼠脑中区域性特异性分布并且在大脑皮层、海马体和杏仁核中富集，脑区域特异性发生脂代谢紊乱，线粒体代谢功能障碍	糖酵解和戊糖磷酸途径（PPP）	[62]
其他	乙肝	MALDI-MSI	磷脂酰胆碱显著减少	胆碱代谢	[64-65]
	传染病	MALDI-MSI	脂质A、肉毒素（SAP1）、前列腺素E2（PGE2）代谢异常	脂肪酸代谢	[63]
	动脉粥样硬化	DESI-MSI、MALDI-MSI	鞘磷脂和氧化胆固醇酯丰度上调	坏死性凋亡、鞘脂信号通路和甘油磷脂代谢	[83]
	视网膜病变	MALDI-MSI	磷脂酰乙醇胺在病变部位丰度下调，鞘氨醇髓鞘则更丰富	氨基酸代谢	[84]
	心力衰竭	TOF-SIMS imaging	存在差异代谢谱，细胞中代谢差异体现在溶血磷脂酸、PI、PE	脂质代谢	[85]